Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.65 USD | +3.31% | -0.14% | -9.18% |
Sales 2024 * | 200M 273M | Sales 2025 * | 261M 357M | Capitalization | 1.2B 1.65B |
---|---|---|---|---|---|
Net income 2024 * | -195M -267M | Net income 2025 * | -163M -223M | EV / Sales 2024 * | 4.46 x |
Net cash position 2024 * | 313M 427M | Net cash position 2025 * | 217M 297M | EV / Sales 2025 * | 3.79 x |
P/E ratio 2024 * |
-6.79
x | P/E ratio 2025 * |
-8.43
x | Employees | 355 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 69.98% |
Latest transcript on Deciphera Pharmaceuticals, Inc.
1 day | +3.31% | ||
1 week | -0.14% | ||
Current month | -6.87% | ||
1 month | -3.49% | ||
3 months | +2.73% | ||
6 months | +44.33% | ||
Current year | -9.18% |
Managers | Title | Age | Since |
---|---|---|---|
Steven Hoerter
CEO | Chief Executive Officer | 53 | 18-05-16 |
Tucker Kelly
DFI | Director of Finance/CFO | 53 | 15-01-31 |
Kevin Brodbeck
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Patricia Allen
BRD | Director/Board Member | 62 | 16-08-31 |
Edward Benz
BRD | Director/Board Member | 78 | 19-06-30 |
Ron Squarer
CHM | Chairman | 57 | 19-12-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 0 M€ | 0.00% | - | |
0.07% | 0 M€ | 0.00% | - | |
0.05% | 2 M€ | -.--% | ||
0.04% | 237 M€ | +2.89% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 14.65 | +3.31% | 330,362 |
24-04-25 | 14.18 | -3.01% | 527,033 |
24-04-24 | 14.62 | -0.34% | 401,815 |
24-04-23 | 14.67 | +0.62% | 426,396 |
24-04-22 | 14.58 | -0.61% | 611,443 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.18% | 1.2B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- DCPH Stock